<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Background: To assess the safety and efficacy of percutaneous <z:hpo ids='HP_0001655'>patent foramen ovale</z:hpo> (<z:mp ids='MP_0004225'>PFO</z:mp>) closure for the prevention of recurrent <z:hpo ids='HP_0001297'>stroke</z:hpo> in high-risk patients.Methods and results: Between January 2002 and March 2005, 40 patients (65% female), mean (SD) age 43 (10) years were identified using the following inclusion criteria: &lt;60 years, recent <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> (&lt;3 months), combination of <z:mp ids='MP_0004225'>PFO</z:mp> plus <z:hpo ids='HP_0011995'>atrial septal aneurysm</z:hpo> (<z:chebi fb="37" ids="15365">ASA</z:chebi>) and exclusion of any other thromboembolic cause </plain></SENT>
<SENT sid="1" pm="."><plain>Percutaneous <z:mp ids='MP_0004225'>PFO</z:mp> closure was performed under general anaesthesia and under the guidance of transoesophageal echocardiography (TEE) </plain></SENT>
<SENT sid="2" pm="."><plain>Aspirin and <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> were given for three months after <z:mp ids='MP_0004225'>PFO</z:mp> closure, followed by aspirin alone </plain></SENT>
<SENT sid="3" pm="."><plain>Neurological examination was performed every three months.Results: <z:mp ids='MP_0004225'>PFO</z:mp> closure was successful in <z:hpo ids='HP_0000001'>all</z:hpo> patients, using <z:hpo ids='HP_0000001'>all</z:hpo> devices: INTRASEPT in 34 cases, STARFlex in 5 cases and AMPLATZER in one case </plain></SENT>
<SENT sid="4" pm="."><plain>At day one, transthoracic echocardiography (TTE) excluded malpositioning of the device or <z:hpo ids='HP_0001698'>pericardial effusion</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>At 6 months, TTE and TEE confirmed satisfactory implantation of the device, with no spontaneous shunt </plain></SENT>
<SENT sid="6" pm="."><plain>No device related <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> was observed </plain></SENT>
<SENT sid="7" pm="."><plain>Mean patient follow-up was 17+/-7 months (range 12-38) and was 100% complete </plain></SENT>
<SENT sid="8" pm="."><plain>No patients suffered from recurrent <z:hpo ids='HP_0001297'>stroke</z:hpo> (neither <z:e sem="disease" ids="C0007787" disease_type="Disease or Syndrome" abbrv="tia|TIA|T.I.A.">transient ischaemic attack</z:e> nor <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e>).Conclusion: This preliminary experience is encouraging for <z:mp ids='MP_0004225'>PFO</z:mp> closure with a 0% risk of <z:hpo ids='HP_0001297'>stroke</z:hpo> recurrence rate in a high-risk subset of patients (&lt; 60 years, recent cryptogenic <z:hpo ids='HP_0001297'>stroke</z:hpo>, <z:mp ids='MP_0004225'>PFO</z:mp> plus <z:chebi fb="37" ids="15365">ASA</z:chebi>) and is safe using the current technology </plain></SENT>
<SENT sid="9" pm="."><plain>Larger series with longer follow-up and randomised studies are still necessary in this setting before the completion of guidelines </plain></SENT>
</text></document>